Alcoholic Hepatitis Pipeline Insight
DelveInsight’s, “Alcoholic Hepatitis – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Alcoholic Hepatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Alcoholic Hepatitis Understanding
Alcoholic Hepatitis: Overview
Alcoholic hepatitis is a diseased, inflammatory condition of the liver caused by heavy alcohol consumption over an extended period of time. It’s also aggravated by binge drinking and ongoing alcohol use. When alcohol gets processed in the liver, it produces highly toxic chemicals. These chemicals can injure the liver cells. This injury then leads to inflammation, and alcoholic hepatitis. Over time, scars begin to replace functional liver tissue in the body. This interferes with how the liver works. Irreversible scarring — or cirrhosis — is the final stage of alcoholic liver disease. Because alcoholic hepatitis doesn’t occur in all people who excessively use alcohol, other factors may influence the development of this condition. These include: genetic factors that affect how the body processes alcohol, the presence of liver infections or other liver disorders, such as hepatitis B, hepatitis C, and hemochromatosis, malnutrition, and being overweight. One of the most common signs of alcoholic hepatitis is jaundice, or yellowing of the skin and eyes. Additional symptoms include: loss of appetite, nausea, vomiting, stomach pain, fever, tiredness, and weakness. Blood tests to determine alcoholic hepatitis include: liver function studies, cellular blood counts, measuring bleeding times, electrolyte tests, and tests for other chemicals in the body. The main treatment for alcoholic hepatitis is to stop consuming alcohol. There is no cure for alcoholic hepatitis, but treatment will aim to reduce or eliminate symptoms and stop the progression of the disease.
"Alcoholic Hepatitis - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alcoholic Hepatitis pipeline landscape is provided which includes the disease overview and Alcoholic Hepatitis treatment guidelines. The assessment part of the report embraces, in depth Alcoholic Hepatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alcoholic Hepatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Alcoholic Hepatitis R&D. The therapies under development are focused on novel approaches to treat/improve Alcoholic Hepatitis.
Alcoholic Hepatitis Emerging Drugs Chapters
This segment of the Alcoholic Hepatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alcoholic Hepatitis Emerging Drugs
DUR-928 is an investigational product and has not been approved by the FDA for marketing in the U.S. for any indication. DURECT is currently conducting a Phase IIb study (AHFIRM) in subjects with severe alcohol-associated hepatitis (also called Alcoholic Hepatitis or AH) to evaluate safety and efficacy of DUR-928 treatment. DUR-928 has been shown to inhibit the activity of DNMTs (DNMT-1, 3a and 3b), inhibiting DNA methylation, and upregulating expression of genes involved in signaling pathways associated with cell death, stress response, and lipid biosynthesis, which may ultimately result in increased cell survival, reduced inflammation, and decreased lipotoxicity.
Canakinumab is a licensed monoclonal antibody inhibitor of IL-1 and may consequently reverse the adverse effects of the cytokine in patients with this disorder. Therefore, the main objective of the Phase II ISAIAH trial is to explore the potential benefits of the IL-1β antibody, Canakinumab (solution for injection), in the treatment of alcoholic hepatitis.
Further product details are provided in the report……..
Alcoholic Hepatitis: Therapeutic Assessment
This segment of the report provides insights about the different Alcoholic Hepatitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Alcoholic Hepatitis
There are approx. 10+ key companies which are developing the therapies for Alcoholic Hepatitis. The companies which have their Alcoholic Hepatitis drug candidates in the most advanced stage, i.e. Phase III include, Durect.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Alcoholic Hepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Alcoholic Hepatitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alcoholic Hepatitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alcoholic Hepatitis drugs.
Alcoholic Hepatitis Report Insights
- Alcoholic Hepatitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Alcoholic Hepatitis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Alcoholic Hepatitis drugs?
- How many Alcoholic Hepatitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alcoholic Hepatitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alcoholic Hepatitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Alcoholic Hepatitis and their status?
- What are the key designations that have been granted to the emerging drugs?